2010-05-19

The French Competition Authority Follows up Allegations of Anti-competitive Practices by Sanofi-Aventis to Exclude Fair Generic Competition for Plavix(R) (clopidogrel)


Utrecht, The Netherlands, May 19, 2010 (ots/PRNewswire) - Teva Santé,one of France's leading generic medicines companies, has welcomednews that the French Competition Authority has agreed to its requestto investigate alleged anti-competitive practices by Sanofi-Aventisaimed at preventing generic competition to its Plavix(R)(clopidogrel) treatment.

In November last year, Teva Santé filed a complaint with theFrench Competition Authority against alleged practices bySanofi-Aventis which, according to Teva Santé, had the effect ofexcluding generic drugs competing with Plavix(R) including Teva's ownclopidogrel generic medicine.

In its decision published yesterday, the French CompetitionAuthority said that it intends to carry out an in-depth investigationon alleged behaviour by Sanofi-Aventis to shut out genericcompetition.

According to the Authority, Sanofi-Aventis' communications towardscientists and practitioners emphasise differences between Plavix(R)and competing generics (including Clopidogrel Teva Pharma 75 mg)without revealing that these differences have no impact on thetherapeutic efficacy of the product, and that the generic formulationhas been fully tested and approved for use by medical authoritiesacross Europe.

Dr. Gerard van Odijk, CEO of Teva Europe, welcomed theAuthority's ruling: "We believe in a fair and open market thatdelivers affordable healthcare for patients and the taxpayer acrossEurope. The Authority's decision to investigate Sanofi-Aventis'behaviour underlines our view that such practices are likely toprevent access to competition and damage the long-term interests ofpatients."

Maurice Chagnaud, CEO of Teva Santé, said: "Innovator companiesneed to understand that they cannot use misleading practices toprevent competition from therapeutically equivalent and effectivegeneric products. Generic medicines help make healthcare affordable,and we consider that practices aimed at stifling fair competition areunlawful."

Teva Pharmaceuticals Europe BV

Computerweg 10, 3542 DR Utrecht, Netherlands

Teva Pharmaceutical Industries Ltd. , headquartered in Israel, isamong the top 15 pharmaceutical companies in the world and is theleading generic pharmaceutical company. The company develops,manufactures and markets generic and innovative pharmaceuticals andactive pharmaceutical ingredients. Over 80 percent of Teva's salesare in North America and Western Europe.

ots Originaltext: Teva Pharmaceuticals Europe BVIm Internet recherchierbar: http://www.presseportal.de

Contact:CONTACT: Media contact: Paul Williams, Teva Europe, +44(0)7798-582889,paul.williams@tevauk.com

Teva Pharmaceuticals Europe BV

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs

News

The French Competition Authority Follows up Allegations of Anti-competitive Practices by Sanofi-Aventis to Exclude Fair Generic Competition for Plavix(R) (clopidogrel)

Medizin-News